Sanofi Consumer Healthcare India Reports Strong Q3'26 Financial Performance
Sanofi Consumer Healthcare India Ltd · Press Release · 29 Oct 2026, 12:22 am
Sanofi Consumer Healthcare India Reports Strong Q3'26 Financial Performance Sanofi Consumer Healthcare India reported Q3'26 revenue from operations of ₹2,631 million, up 12% YoY (11.6% QoQ), with product sales rising 14.4% YoY to ₹2,438 million led by 19% domestic sales growth. Profit before tax rose 22.1% YoY to ₹1,027 million, while net profit grew 21.8% YoY to ₹766 million (₹688 million in Q2'26), yielding an EPS of ₹33.26. For 9M'26, revenue increased 16.0% YoY to ₹7,280 million, PBT rose 24.2% YoY to ₹2,853 million, and net profit expanded 22.8% YoY to ₹2,132 million.
Original exchange filing (PDF)
More announcements from Sanofi Consumer Healthcare India Ltd
- Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated October 28, 2026. · 29 Oct 2026
- Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter and nine months ended September 30, 2026. · 29 Oct 2026
- Unaudited Financial Results for the quarter and nine months ended September 30, 2026 is enclosed. · 29 Oct 2026
- We wish to inform you that the Board of Directors at its meeting held today, i.e. Wednesday, 28th October 2026, inter alia considered and approved the Unaudited Financial Results for the .... · 28 Oct 2026
- Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 28 Oct 2026
- Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve the Unaudited .... · 28 Oct 2026
- Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 28 Oct 2026
- To consider and approve the Unaudited Financial Results for the quarter and nine months ended September 30, 2026 · 28 Oct 2026
